Literature DB >> 12490593

Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human alpha4beta2- and alpha4beta4-nicotinic acetylcholine receptors.

Cynthia L Gentry1, Lincoln H Wilkins, Ronald J Lukas.   

Abstract

Effects of prolonged nicotinic ligand exposure on the function of human alpha4beta2- and alpha4beta4-nicotinic acetylcholine receptor (nAChR) subtypes were studied using receptors heterologously expressed in SH-EP1 human epithelial cells. Magnitudes of acute, nAChR-mediated, specific 86Rb+ efflux responses to 1 mM carbamylcholine were reduced after pretreatment with specific nAChR ligands in effects that depended on pretreatment drug dose, duration of drug pretreatment, and duration of drug-free recovery. Fifty percent inhibition of alpha4beta2-nAChR function following 5 min of recovery occurred after 1 min of pretreatment with 1 mM nicotine but also after 1-h pretreatment at 10 nM nicotine. Seventy-five percent loss in function persisted 1 h after drug removal following 15 min or more of exposure to 1 mM nicotine. However, functional recovery was nearly complete after 1 h in drug-free medium following 1 min to 24 h pretreatment with 0.1 to 1 microM nicotine, i.e., in the range of smoker plasma nicotine levels. alpha4beta4-nAChR was similarly sensitive to persistent inactivation by prolonged nicotine exposure. Carbamylcholine exhibited slightly lower persistent inactivation potency than nicotine at both alpha4beta2- and alpha4beta4-nAChR. The nAChR antagonist, mecamylamine, exhibited persistent inactivation potency and efficacy similar to nicotine at alpha4beta2-nAChR but had a reduced effect on alpha4beta4-nAChR. These studies illustrate persistent inactivation of human alpha4beta2- or alpha4beta4-nAChR induced by prolonged exposure to nicotine and show that other ligands induce nAChR persistent inactivation in a subtype-specific manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490593     DOI: 10.1124/jpet.102.041756

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

Review 2.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

3.  Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice.

Authors:  Jennifer A Davis; John R James; Steven J Siegel; Thomas J Gould
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

4.  Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors.

Authors:  Jie Wu; Qiang Liu; Kewei Yu; Jun Hu; Yen-Ping Kuo; Marsha Segerberg; Paul A St John; Ronald J Lukas
Journal:  J Physiol       Date:  2006-07-06       Impact factor: 5.182

5.  Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include α5 or α6 subunits and that mediate synaptosomal neurotransmitter release.

Authors:  Sharon R Grady; Charles R Wageman; Natalie E Patzlaff; Michael J Marks
Journal:  Neuropharmacology       Date:  2012-01-02       Impact factor: 5.250

6.  Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Authors:  Jonathan D Raybuck; George S Portugal; Caryn Lerman; Thomas J Gould
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

7.  Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells.

Authors:  Kewei D Yu; Qiang Liu; Jie Wu; Ronald J Lukas
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

8.  The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype.

Authors:  J Brek Eaton; Linda M Lucero; Harrison Stratton; Yongchang Chang; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  J Pharmacol Exp Ther       Date:  2013-11-04       Impact factor: 4.030

9.  Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats.

Authors:  Hakan Kayir; Svetlana Semenova; Athina Markou
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-09-20       Impact factor: 5.067

Review 10.  A psychobiological framework of the substrates that mediate nicotine use during adolescence.

Authors:  Laura E O'Dell
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.